FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileCyclopharm Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CYC.AX
Cyclopharm Limited Stock AnalysisComprehensive stock analysis for Cyclopharm Limited (CYC.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisCYC.AX
CYC.AX
Cyclopharm Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
CYC.AX
  1. Home
  2. Stocks
  3. Cyclopharm Limited

Cyclopharm Limited

🇦🇺CYC.AX•ASX

Cyclopharm Limited

🇦🇺CYC.AX•ASX

Your view on CYC.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Cyclopharm Limited

Industry
Medical - Devices
Sector
Healthcare
CEO
James S. McBrayer BSPharm
Headquarters
1 The Crescent, Kingsgrove, NSW, AU
Industry
Medical - Devices
Sector
Healthcare
CEO
James S. McBrayer BSPharm
Headquarters
1 The Crescent, Kingsgrove, NSW, AU
Description

Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging.

Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector.

Conversely, the Molecular Imaging division provides advanced radiopharmaceutical agents essential for medical practitioners diagnosing conditions such as cancer, various neurological disorders, and cardiac diseases. Cyclopharm primarily serves nuclear medicine departments.

Established in 1986, the company's corporate headquarters are located in Kingsgrove, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Cyclopharm Limited. Starting points for Cyclopharm Limited: EPS -AUD 0.15, beta 0.57 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Cyclopharm Limited. Cyclopharm Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Cyclopharm Limited. Trailing twelve-month EPS for Cyclopharm Limited stands at -AUD 0.15. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 20, 2026 · AUD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Earnings Estimate

EPSCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimateAUD 0.00−AUD 0.14−AUD 0.09
Low estimateAUD 0.00−AUD 0.14−AUD 0.09
High estimateAUD 0.00−AUD 0.14−AUD 0.09
No. of analysts011
Year-ago EPS−AUD 0.05−AUD 0.161—
Growth+100.0%——

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimateAUD 19.70MAUD 37.20MAUD 47.20M
Low estimateAUD 19.70MAUD 37.20MAUD 47.20M
High estimateAUD 19.70MAUD 37.20MAUD 47.20M
No. of analysts111
Year-ago revenueAUD 14.37MAUD 32.33M—
Growth+37.1%+15.1%—

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep; as of Nov 20, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Cyclopharm Limited. Cyclopharm Limited has reported as a listed company since 2007. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold CYC.AX19 companies
Compare CYC.AX with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustry
ATX.AXAmplia Therapeutics LimitedHealthcareBiotechnology—
BMT.AXBeamtree Holdings LimitedHealthcareMedical - Healthcare Information Services—
CMP.AXCompumedics LimitedHealthcareMedical - Devices—
CSX.AXCleanSpace Holdings LimitedHealthcareMedical - Devices—
CYP.AXCynata Therapeutics LimitedHealthcareBiotechnology—
GSS.AXGenetic Signatures LimitedHealthcareMedical - Diagnostics & Research—
IPD.AXImpediMed LimitedHealthcareMedical - Devices—
M7T.AXMach7 Technologies LimitedHealthcareMedical - Healthcare Information Services—
More Medical - Devices companies
TickerTypeCompanySectorExchangeMkt cap
CBL.AXControl Bionics LimitedHealthcareASX—
CBLLCeriBell, Inc.HealthcareNASDAQ$995.3M
CERSCerus CorporationHealthcareNASDAQ$391.8M
CGHCCapital Group Holdings, Inc.HealthcareOTC$9,220
CHEOFCochlear LimitedHealthcareOTC$8.9B
CHEOYCochlear LimitedHealthcareOTC$9.2B
CHYPFHealth Logic Interactive Inc.HealthcareOTC$165,839
CLLKFBICO Group AB (publ)HealthcareOTC$123.3M
CLPTClearPoint Neuro, Inc.HealthcareNASDAQ$247.1M
CLVSFCellaVision AB (publ)HealthcareOTC$378.0M
CNMDCONMED CorporationHealthcareNYSE$1.4B
Open Comparable Analysis
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Cyclopharm Limited. Coverage tracks Cyclopharm Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Cyclopharm Limited.

CYC.AX AnalysisFair
Past
1
Growth
3
Health
4
Profit
1
Value
1

News

Latest Market News